Literature DB >> 10648420

CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines.

G Teoh1, Y T Tai, M Urashima, S Shirahama, M Matsuzaki, D Chauhan, S P Treon, N Raje, T Hideshima, Y Shima, K C Anderson.   

Abstract

It has been reported that the activation of multiple myeloma (MM) cells by CD40 induces proliferation, growth arrest, and apoptosis. To determine whether the biologic sequelae of CD40 activation in MM cells depends on p53 function, we identified temperature-sensitive p53 mutations in the RPMI 8226 (tsp53E285K) and the HS Sultan (tsp53Y163H) MM cell lines. These cells were then used as a model system of inducible wtp53-like function because wild-type-like p53 is induced at permissive (30 degrees C) but not at restrictive (37 degrees C) temperatures. Using p21-luciferase reporter assays, we confirmed that CD40 induces p53 transactivation in RPMI 8226 and HS Sultan cells cultured under permissive, but not restrictive, conditions. Furthermore, CD40 activation of these MM cells under permissive, but not restrictive, temperatures increased the expression of p53 and p21 mRNA and protein. Importantly, CD40 activation induced the proliferation of RPMI 8226 and HS Sultan cells at restrictive temperatures and growth arrest and increased subG1 phase cells at permissive temperatures. These data confirmed that CD40 activation might have distinct biologic sequelae in MM cells, depending on their p53 status.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10648420

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Molecular mechanism and function of CD40/CD40L engagement in the immune system.

Authors:  Raul Elgueta; Micah J Benson; Victor C de Vries; Anna Wasiuk; Yanxia Guo; Randolph J Noelle
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

2.  Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.

Authors:  Sally A Hunsucker; Valeria Magarotto; Deborah J Kuhn; Steven M Kornblau; Michael Wang; Donna M Weber; Sheeba K Thomas; Jatin J Shah; Peter M Voorhees; Hong Xie; Mark Cornfeld; Jeffrey A Nemeth; Robert Z Orlowski
Journal:  Br J Haematol       Date:  2011-01-17       Impact factor: 6.998

3.  Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice.

Authors:  D Wang; Y Fløisand; C V Myklebust; S Bürgler; A Parente-Ribes; P O Hofgaard; B Bogen; K Taskén; G E Tjønnfjord; F Schjesvold; J Dalgaard; A Tveita; L A Munthe
Journal:  Leukemia       Date:  2017-02-24       Impact factor: 11.528

4.  CSNK1α1 mediates malignant plasma cell survival.

Authors:  Y Hu; W Song; D Cirstea; D Lu; N C Munshi; K C Anderson
Journal:  Leukemia       Date:  2014-06-25       Impact factor: 11.528

5.  Signaling mechanisms of bortezomib in TRAF3-deficient mouse B lymphoma and human multiple myeloma cells.

Authors:  Shanique K E Edwards; Yeming Han; Yingying Liu; Benjamin Z Kreider; Yan Liu; Sukhdeep Grewal; Anand Desai; Jacqueline Baron; Carissa R Moore; Chang Luo; Ping Xie
Journal:  Leuk Res       Date:  2015-12-19       Impact factor: 3.156

6.  Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.

Authors:  Victoria J Spanswick; Helen L Lowe; Claire Newton; John P Bingham; Alessia Bagnobianchi; Konstantinos Kiakos; Charles Craddock; Jonathan A Ledermann; Daniel Hochhauser; John A Hartley
Journal:  BMC Cancer       Date:  2012-09-28       Impact factor: 4.430

7.  CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways.

Authors:  Nathalie Voorzanger-Rousselot; Laurent Alberti; Jean-Yves Blay
Journal:  BMC Cancer       Date:  2006-03-18       Impact factor: 4.430

8.  DEPTOR is linked to a TORC1-p21 survival proliferation pathway in multiple myeloma cells.

Authors:  Yonghui Yang; Carolyne Bardeleben; Patrick Frost; Bao Hoang; Yijiang Shi; Richard Finn; Joseph Gera; Alan Lichtenstein
Journal:  Genes Cancer       Date:  2014-11

Review 9.  CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges.

Authors:  Xiaomin Zhang; Lingling Zhu; Hui Zhang; Shanshan Chen; Yang Xiao
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 10.  Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.

Authors:  TingTing Tang; Xiang Cheng; Billy Truong; LiZhe Sun; XiaoFeng Yang; Hong Wang
Journal:  Pharmacol Ther       Date:  2020-10-20       Impact factor: 12.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.